Episode 15: Part 2: Immunobullous disorders - Pemphigus vulgaris Artwork

St John's DermAcademy Podcast

Our Podcasts are delivered to you by clinicians and academics at St John’s Institute of Dermatology and invited speakers. Our aim is to update you and share practical tips on how experts in their field diagnose and treat common dermatological conditions in our short episodes that you can easily listen to whilst on the go. Our podcasts are targeted at healthcare professionals including dermatology consultants, dermatology trainees, GPs and specialist nurses. Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical they may have.

All Episodes

St John's DermAcademy Podcast

Episode 15: Part 2: Immunobullous disorders - Pemphigus vulgaris

June 07, 2024 • St John's DermAcademy • Episode 15

In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about pemphigus vulgaris:

• The clinical features of pemphigus vulgaris and other variants of pemphigus.
• The step-wise management of pemphigus vulgaris including an approach to managing severe disease and the use of rituximab and intravenous immunoglobulin .

Resources and further reading:
• British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris, 2017 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15930)
• European guidelines for the management of pemphigus vulgaris and foliaceous initiated by the European Academy of Dermatology and Venereology, 2020 (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752)
• Rituximab and Covid-19 Risk – a single-centre cohort study (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00004-8/fulltext)
• Phase 2 Study of efficacy and safety of Rilzabrutinib for patients with pemphigus vulgaris (https://pubmed.ncbi.nlm.nih.gov/35686647/)
• Phase 2 Study of the use of Efgartigimod for patients with pemphigus vulgaris and foliaceous (https://pubmed.ncbi.nlm.nih.gov/34608631/)

Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.

Recorded date: 26 January 2024